Aurora Expands Medical Cannabis Portfolio in Germany

01 May 2023 | Monday | News

New flower varieties for patients with high THC needs
Image Source| Public Domain

Image Source| Public Domain

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and a leading manufacturer and supplier of dried flower for medical patients worldwide, today announced the expansion of its portfolio in Germany with the launch of two new cannabis flower products for patients. Pedanios 27/1 FRG CA and Pedanios 29/1 SRD CA are dried cannabis flower with high tetrahydrocannabinol (THC) content. With these new therapeutic options now available, the Company will better meet the individual medical needs of its patients.

"The addition of these two high-THC products to our German portfolio gives physicians even more options to provide patients individually tailored treatments," says Dr. Axel Gille, President of Aurora Europe. "We are committed to bringing high quality, consistent and innovative cannabis products to our patients in Germany and throughout Europe."

Providing patients with a broad spectrum of cannabis products and formats is important to individualized and patient-specific care. With this portfolio expansion, Aurora solidifies its international market-leading position in medical cannabis.

Pedanios 27/1 FRG CA is medical cannabis flower from the Farm Gas cultivar, with a THC content of about 27% and a cannabidiol (CBD) content of <1%. This cultivar is known for its complex aromas and fruity undertones.

Pedanios 29/1 SRD CA is medical cannabis flower from the Sourdough cultivar, with approximately 29% THC and <1% CBD. Both Farm Gas and Sourdough are proprietary cultivars developed by Aurora's leading science and innovation business, Occo. They are grown to the highest quality standards under EU GMP certified conditions, hang-dried, hand finished, and hand bottled, resulting in an exceptional product.

In addition, the Company announced it has filed a final short form base shelf prospectus with securities regulators in each of the provinces of Canada, except Quebec, and a corresponding shelf registration statement on Form F–10 with the United States Securities and Exchange Commission.

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close